AstraZeneca (STU:ZEGA) Cyclically Adjusted PS Ratio: (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:ZEGA AstraZeneca PLC STU:ZEGA
88 GF Score
Price €78.00
GF Value €80.74
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca  (STU:ZEGA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


AstraZeneca Cyclically Adjusted PS Ratio Related Terms


AstraZeneca Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for AstraZeneca's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Cyclically Adjusted PS Ratio Chart

AstraZeneca Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.51 6.30 5.52 5.02 6.09

AstraZeneca Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.63 5.03 6.09 6.37 5.98

STU:ZEGA vs LLY, JNJ, ABBV: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PS Ratio falls into.


STU:ZEGA
88GF Score
AstraZeneca PLC STU:ZEGA
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

AstraZeneca's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, AstraZeneca's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=4.307/142.1000*142.1000
=4.307

Current CPI (Jun. 2026) = 142.1000.

AstraZeneca Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 2.005 101.500 2.807
201612 2.091 102.200 2.907
201703 1.996 102.700 2.762
201706 1.775 103.500 2.437
201709 2.063 104.300 2.811
201712 1.922 105.000 2.601
201803 1.657 105.100 2.240
201806 1.741 105.900 2.336
201809 1.806 106.600 2.407
201812 2.226 107.100 2.953
201903 1.916 107.000 2.545
201906 1.964 107.900 2.587
201909 2.217 108.400 2.906
201912 2.284 108.500 2.991
202003 2.190 108.600 2.866
202006 2.122 108.800 2.771
202009 2.128 109.200 2.769
202012 2.320 109.400 3.013
202103 2.331 109.700 3.019
202106 2.588 111.400 3.301
202109 2.803 112.400 3.544
202112 3.403 114.700 4.216
202203 3.313 116.500 4.041
202206 3.266 120.500 3.851
202209 3.557 122.300 4.133
202212 3.391 125.300 3.846
202303 3.257 126.800 3.650
202306 3.377 129.400 3.708
202309 3.451 130.100 3.769
202312 3.532 130.500 3.846
202403 3.739 131.600 4.037
202406 3.852 133.000 4.116
202409 3.912 133.500 4.164
202412 4.552 135.100 4.788
202503 4.026 136.100 4.203
202506 4.020 138.400 4.127
202509 4.146 138.900 4.242
202512 4.270 139.900 4.337
202603 4.265 140.800 4.304
202606 4.307 142.100 4.307

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is AstraZeneca (STU:ZEGA) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of €78.00 is trading 3.4% below its estimated GF Value™ of €80.74.

Key valuation signals for STU:ZEGA:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €80.74 vs. price of €78.00 (3.4% below fair value)
  • GF Score™: 88/100 with 1 warning sign

No single metric tells the full story. See the STU:ZEGA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
88GF Score

Get the complete analysis for STU:ZEGA

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€78.00
Price
€80.74
GF Value